Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases

A multi-functional chimeric hematopoietic protein comprising an amino acid sequence of the formula: R1-L1-R2, R2-L1-R1, R1-R2 or R2-R1 Wherein R1 and R2 are independently selected from the group consisting of; (I) A human EPO receptor agonist polypeptide, comprising a modified EPO as shown in Sequence ID 464, wherein 1-6 amino acids from the N-terminus and/or 1-5 from the C-terminus are optionally deleted. The N-terminus is joined to the C-terminus directly or through a linker (L2). (II) A human stem cell factor receptor agonist polypeptide comprising a modified stem cell factor as shown in Sequence ID 465, wherein 1-23 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (III) A human flt-3 receptor agonist polypeptide comprising a modified flt-3 ligand as shown in Sequence ID 466, wherein 1-7 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (IV) A human G-CSF polypeptide comprising a modified human G-CSF as shown in Sequence ID 858, wherein Xaa may be replaced with any of the disclosed amino acids and 1-11 amino acids and/or 1-5 amino acids are optionally deleted from the C-terminus. The N-terminus is joined to the C-terminus directly or through a linker (L2). (V) A human IL-3 polypeptide comprising a modified human IL-3 as shown in Sequence ID 859 whereupon the modified IL-3 is circularly permuted, wherein Xaa may be replaced with any of the disclosed amino acids and 1-14 amino acids and/or 1-15 amino acids are optionally deleted from the C-terminus and amino acids 0-44 designated Xaa are different to the corresponding native human IL-3 (1-133). The N-terminus is joined to the C-terminus directly or through a linker (L2). (VI) A human c-mpl ligand polypeptide comprising a modified human c-mpl ligand as shown in Sequence ID 860, wherein Xaa may be replaced with any of the disclosed amino acids. The N-terminus is joined to the C-terminus directly or through a linker (L2). (VII) A human IL-3 polypeptide comprising a modified human IL-3 as shown in Sequence ID 859, wherein Xaa may be replaced with any of the disclosed amino acids and 1-14 amino acids and/or 1-15 amino acids are optionally deleted from the C-terminus and amino acids 0-44 designated Xaa are different to the corresponding native human IL-3 (1-133). The N-terminus is joined to the C-terminus directly or through a linker (L2). (VIII